Compare Ascendis Pharma A/S (ASND) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while YieldMax Universe Fund of Option Income ETFs trades at $7.85. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ASND | YMAX | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $14.00 |
52-Week Low | $163.32 | $7.51 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
YMAX trades at $7.92, down 0.75% today, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, though key valuation and profitability metrics remain unavailable. Recent news highlights the fund's focus on generating income through covered call strategies on a portfolio of YieldMax ETFs.
The outlook centers on YMAX's high distribution yield strategy, which faces headwinds from the bearish moving average signal and market volatility dependence. Investment appeal lies in income generation, but risks include the fund's complex options strategy and expense ratio of 1.33%, with most distributions representing return of capital rather than earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
